- Live video webcast roundtable with members from the
Moleculin Management Team and Dr. Tallman to discuss the unmet
medical needs in the treatment of acute myeloid leukemia (AML),
Annamycin and the Company's AML clinical development program as
well as data demonstrated to date
- Ongoing development progress of Annamycin toward pivotal AML
study in 2024 with potential qualification for an accelerated
approval pathway
HOUSTON, May 2, 2024
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
(Moleculin or the Company), a clinical stage pharmaceutical
company with a broad portfolio of drug candidates targeting
hard-to-treat tumors and viruses, today announced that it will host
a virtual AML Clinical Day on Tuesday,
May 7, 2024 at 11:00 AM
ET.
For the event, Walter Klemp,
Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of
Moleculin will be joined by key opinion leader, Dr. Martin Tallman.
Dr. Tallman is an internationally renowned clinical investigator
whose discoveries have fueled the progress of leukemia-targeting
therapies, most recently with the Robert H. Lurie Comprehensive
Cancer Center of Northwestern
University. Prior to his role at Lurie Cancer Center where
he focused on the management and development of new treatments for
patients with both acute and chronic leukemias, he was at Memorial
Sloan Kettering Cancer Center where he served as chief of the
Leukemia Service and Professor of Medicine at the Weill Cornell
Medical College in New York. He
was the president of the American Society of Hematology (ASH) in
2021, chaired the Leukemia Committee of the Eastern Cooperative
Oncology Group (ECOG) for 16 years, and served as immediate past
chair of the National Comprehensive Cancer Network (NCCN) Acute
Myeloid Leukemia Panel. Dr. Tallman previously served at
Northwestern University Feinberg School
of Medicine as Professor of Medicine prior to his appointment at
Sloan Kettering. The Company recently announced Dr. Tallman's
agreement to join the newly constituted Annamycin Science Advisory
Board.
As part of the discussion, the Moleculin team and Dr. Tallman
will provide an overview of Annamycin, the treatment landscape for
AML and how Annamycin is positioned to address a significant unmet
medical need. Additionally, the Company will discuss the Annamycin
AML data demonstrated to date. Click here to register for the
event.
A live video webcast of the event will be available on the
Events page under the Investors section of the Company's website
(moleculin.com). A webcast replay will be available two hours
following the live event and will be accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases. All interim and
preliminary data discussed above is subject to change.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the timing of the commencement
of a pivotal registration study of Annamycin as a
2nd line therapy in AML before year end. Although
Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin has attempted to identify forward-looking statements by
terminology including 'believes,' 'estimates,' 'anticipates,'
'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,'
'could,' 'might,' 'will,' 'should,' 'approximately' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission (SEC) and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-host-virtual-aml-clinical-day-featuring-internationally-renowned-clinician-martin-s-tallman-md-on-may-7-2024-302133903.html
SOURCE Moleculin Biotech, Inc.